Cited 3 times in
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박용범 | - |
dc.date.accessioned | 2024-03-22T06:04:20Z | - |
dc.date.available | 2024-03-22T06:04:20Z | - |
dc.date.issued | 2023-07 | - |
dc.identifier.issn | 1462-0324 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198376 | - |
dc.description.abstract | OBJECTIVE: To examine the association between MTX, LEF and tacrolimus use and the progression of RA-associated interstitial lung disease (ILD). METHODS: The Korean RA-ILD cohort prospectively enrolled patients with RA-associated ILD at multiple centres from 2015 to 2018 and followed up with them for 3 years. ILD progression was defined by any of the followings: a decrease of ≥10% in forced vital capacity, a decrease of ≥15% in the diffusing capacity of the lung for carbon monoxide, or death from respiratory failure. RESULTS: Of 143 patients, 64 patients experienced ILD progression during a median follow-up period of 33 months. The use of MTX [adjusted hazard ratio (aHR), 1.06; 95% CI, 0.59, 1.89], LEF (aHR, 1.75; 95% CI, 0.88, 3.46) and tacrolimus (aHR, 0.94; 95% CI, 0.52, 1.72) did not increase the risk of ILD progression. However, the association between LEF use and the risk of ILD progression was significant in subgroups with poor lung function (aHR, 8.42; 95% CI, 2.61, 27.15). Older age, male sex, a shorter RA duration, higher RA disease activity and extensive disease at baseline were independently associated with ILD progression. CONCLUSION: None of the three treatments increased the risk of RA-associated ILD progression, except for LEF, which increased the risk of ILD progression in patients with severe ILD. The appropriate use of conventional synthetic disease-modifying antirheumatic drugs considering RA disease activity and ILD severity would be important for the management of RA-associated ILD. © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Oxford University Press | - |
dc.relation.isPartOf | RHEUMATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antirheumatic Agents* / adverse effects | - |
dc.subject.MESH | Arthritis, Rheumatoid* / chemically induced | - |
dc.subject.MESH | Arthritis, Rheumatoid* / complications | - |
dc.subject.MESH | Arthritis, Rheumatoid* / drug therapy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Leflunomide / therapeutic use | - |
dc.subject.MESH | Lung Diseases, Interstitial* / complications | - |
dc.subject.MESH | Lung Diseases, Interstitial* / etiology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Methotrexate / adverse effects | - |
dc.subject.MESH | Tacrolimus / adverse effects | - |
dc.title | Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Ji-Won Kim | - |
dc.contributor.googleauthor | Sang Wan Chung | - |
dc.contributor.googleauthor | Jung Yoon Pyo | - |
dc.contributor.googleauthor | Sung Hae Chang | - |
dc.contributor.googleauthor | Min Uk Kim | - |
dc.contributor.googleauthor | Chan Ho Park | - |
dc.contributor.googleauthor | Ji Sung Lee | - |
dc.contributor.googleauthor | Jeong Seok Lee | - |
dc.contributor.googleauthor | You-Jung Ha | - |
dc.contributor.googleauthor | Eun Ha Kang | - |
dc.contributor.googleauthor | Yeon-Ah Lee | - |
dc.contributor.googleauthor | Yong-Beom Park | - |
dc.contributor.googleauthor | Eun Young Lee | - |
dc.contributor.googleauthor | Jung-Yoon Choe | - |
dc.identifier.doi | 10.1093/rheumatology/keac651 | - |
dc.contributor.localId | A01579 | - |
dc.relation.journalcode | J03672 | - |
dc.identifier.eissn | 1462-0332 | - |
dc.identifier.pmid | 36394143 | - |
dc.identifier.url | https://academic.oup.com/rheumatology/article/62/7/2377/6832032 | - |
dc.subject.keyword | LEF | - |
dc.subject.keyword | MTX | - |
dc.subject.keyword | RA | - |
dc.subject.keyword | interstitial lung disease | - |
dc.subject.keyword | progression-free survival | - |
dc.subject.keyword | tacrolimus | - |
dc.contributor.alternativeName | Park, Yong Beom | - |
dc.contributor.affiliatedAuthor | 박용범 | - |
dc.citation.volume | 62 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 2377 | - |
dc.citation.endPage | 2385 | - |
dc.identifier.bibliographicCitation | RHEUMATOLOGY, Vol.62(7) : 2377-2385, 2023-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.